BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, September 23, 2023
Home » Topics » Ocular, BioWorld

Ocular, BioWorld
Ocular, BioWorld RSS Feed RSS

Close up of man's eye

Apellis stock flops on retinal vasculitis reports with newly launched Syfovre

July 18, 2023
By Caroline Richards
No Comments
Apellis Pharmaceutical Inc.’s shares nosedived by 37% July 17 after the American Society of Retina Specialists wrote to ophthalmologists warning them of the risk of serious intraocular inflammation events in patients following injection of the company’s geographic atrophy drug, Syfovre (pegcetacoplan).
Read More
Eye-chart
Newco news

Look sharp: Tenpoint Therapeutics closes $70M series A round to pursue vision

July 12, 2023
By Cormac Sheridan
No Comments
Tenpoint Therapeutics Ltd. raised $70 million in a series A funding round to pursue ambitious plans to reverse vision loss using both ex vivo cell engineering and in vivo cell reprogramming approaches.
Read More
Eye exam

Misdirected focus? Street nicks Viridian shares on upbeat thyroid eye results

July 11, 2023
By Randy Osborne
No Comments
As investors continue to weigh VRDN-001’s chances against Tepezza (teprotumumab, Horizon Pharmaceuticals plc) in thyroid eye disease, Viridian Therapeutics Inc. popped the lid off positive preliminary data from the ongoing phase I/II trial with the intravenous full antagonist antibody to the insulin-like growth factor 1 receptor.
Read More
Eye and DNA illustration

Astellas in-licenses 4DMT’s gene therapy vector for rare ophthalmic targets in $942M deal

July 11, 2023
By Tamra Sami
No Comments
Astellas Pharma Inc. and 4D Molecular Therapeutics Inc. (4DMT) inked a deal worth up to $942 million under which Astellas will license 4DMT's intravitreal R100 gene therapy vector for rare ophthalmic targets.
Read More
Eye wireframe illustration

Eye give-up sees Novartis surrender assets to Bausch – for $2.5B

June 30, 2023
By Randy Osborne
No Comments
Just over a month after scoring U.S. FDA clearance for dry eye disease therapy Miebo (perfluorohexyloctane), Bausch + Lomb Corp. is adding Xiidra (lifitegrast) to its arsenal in the same indication as part of the potential $2.5 billion deal with Novartis AG, which is divesting its “front-of-eye” ophthalmology assets.
Read More

Healios, Sumitomo begin phase I/II trial of allogeneic iPS cells in retinal pigment epithelium tears

June 23, 2023
By Tamra Sami
No Comments
Japan’s Pharmaceutical and Medical Devices Agency has cleared Healios K.K. and Sumitomo Pharma Co. Ltd. to begin a phase I/II study of HLCR-011, which is composed of retinal pigment epithelial (RPE) cells derived from allogeneic induced pluripotent stem cells (iPS) in patients with RPE tear.
Read More
Stock merger illustration

Merger with Talaris to advance Tourmaline’s hidden gem for TED

June 22, 2023
By Karen Carey
No Comments
Less than two years old, Tourmaline Bio Inc. is gaining a public listing through a reverse merger with publicly traded Talaris Therapeutics Inc., as it enters a phase IIb with its lead IL-6 inhibitor for thyroid eye disease (TED).
Read More
Eye illustration
Newco news

Beacon launches with $121M and late-stage eye disease asset

June 12, 2023
By Nuala Moran
No Comments
The lead asset of Applied Genetic Technologies Corp. has been spun into Beacon Therapeutics Ltd., which launches with $120.9 million to run a phase II/III pivotal trial of AGTC-501 in X-linked retinitis pigmentosa, and to take forward two other in-licensed preclinical programs in age-related macular degeneration and cone rod dystrophy.
Read More

AAVantgarde Bio secures $65M series A round for large gene delivery in AAV vectors

June 6, 2023
By Cormac Sheridan
No Comments
AAVantgarde Bio SrL raised €61 million (US$65 million) in series A funding to take forward two novel approaches to gene therapy that aim to overcome the packaging limits of adeno-associated virus (AAV) vectors. The company plans to move its lead program, in retinitis pigmentosa associated with Usher syndrome type 1b, into the clinic later this year. A second program, in Stargardt disease, is a couple of years behind it.
Read More
Eye and DNA

Signs of efficacy seen in Coave's gene therapy trial in RP

May 31, 2023
By Cormac Sheridan
No Comments
Coave Therapeutics aims to move its lead gene therapy program, CTx-PDE6b, for a form of retinitis pigmentosa (RP) into a pivotal trial in 2025 on the back of a phase I/II study, which uncovered a preliminary efficacy signal in one patient subgroup.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 15 16 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing